Free Trial

Pliant Therapeutics (PLRX) Stock Price, News & Analysis

-0.67 (-5.00%)
(As of 05/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
316,969 shs
Average Volume
400,745 shs
Market Capitalization
$768.00 million
P/E Ratio
Dividend Yield
Price Target

Pliant Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
256.4% Upside
$45.38 Price Target
Short Interest
12.51% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.47mentions of Pliant Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($3.44) to ($3.71) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.11 out of 5 stars

Medical Sector

176th out of 917 stocks

Pharmaceutical Preparations Industry

66th out of 409 stocks

PLRX stock logo

About Pliant Therapeutics Stock (NASDAQ:PLRX)

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

PLRX Stock Price History

PLRX Stock News Headlines

Pliant Therapeutics Inc (PLRX)
PLRX Oct 2024 30.000 call
PLRX Oct 2024 7.500 put
See More Headlines
Receive PLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
9 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$1.58 million
Book Value
$7.25 per share


Free Float
Market Cap
$768.00 million
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Bernard Coulie M.B.A. (Age 57)
    M.D., Ph.D., President, CEO & Director
    Comp: $996.97k
  • Dr. Keith Lamont Cummings M.B.A. (Age 47)
    M.D., Chief Financial Officer
    Comp: $684.14k
  • Mr. Mike Ouimette J.D. (Age 51)
    General Counsel & Corporate Secretary
    Comp: $606.03k
  • Mr. Johannes P. Hull (Age 49)
    Chief Business Officer
    Comp: $602.51k
  • Dr. Éric Lefebvre M.D. (Age 60)
    Chief Medical Officer
    Comp: $734.41k
  • Dr. Rik Derynck
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Dean Sheppard M.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Bill DeGrado Ph.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Hal Chapman M.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Craig D. Muir
    Interim Chief Technology Officer

PLRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Pliant Therapeutics stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pliant Therapeutics in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PLRX shares.
View PLRX analyst ratings
or view top-rated stocks.

What is Pliant Therapeutics' stock price target for 2024?

9 equities research analysts have issued 1-year target prices for Pliant Therapeutics' shares. Their PLRX share price targets range from $36.00 to $63.00. On average, they expect the company's share price to reach $45.38 in the next twelve months. This suggests a possible upside of 256.4% from the stock's current price.
View analysts price targets for PLRX
or view top-rated stocks among Wall Street analysts.

How have PLRX shares performed in 2024?

Pliant Therapeutics' stock was trading at $18.11 on January 1st, 2024. Since then, PLRX stock has decreased by 29.7% and is now trading at $12.73.
View the best growth stocks for 2024 here

When is Pliant Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our PLRX earnings forecast

How were Pliant Therapeutics' earnings last quarter?

Pliant Therapeutics, Inc. (NASDAQ:PLRX) issued its earnings results on Monday, May, 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by $0.02.

What ETFs hold Pliant Therapeutics' stock?

ETFs with the largest weight of Pliant Therapeutics (NASDAQ:PLRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

What other stocks do shareholders of Pliant Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pliant Therapeutics investors own include Pfizer (PFE), CrowdStrike (CRWD), Trevena (TRVN), AbbVie (ABBV), Abbott Laboratories (ABT), Archer-Daniels-Midland (ADM), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN).

When did Pliant Therapeutics IPO?

Pliant Therapeutics (PLRX) raised $90 million in an IPO on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler served as the underwriters for the IPO and Needham & Company was co-manager.

Who are Pliant Therapeutics' major shareholders?

Pliant Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (6.56%), First Light Asset Management LLC (5.86%), Vanguard Group Inc. (5.77%), Redmile Group LLC (5.13%), Capital International Investors (2.28%) and Mass General Brigham Inc (0.48%). Insiders that own company stock include Bernard Coulie, Eric Lefebvre, Hans Hull, Keith Lamont Cummings, Matthew Dunnigan and Mike Ouimette.
View institutional ownership trends

How do I buy shares of Pliant Therapeutics?

Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PLRX) was last updated on 5/25/2024 by Staff

From Our Partners